NCT05322577终止1 期
A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Amgen
- 入组人数
- 72
- 试验地点
- 42
- 主要终点
- Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
研究概览
简要总结
The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer not amendable to curative therapy.
- •Ability to provide tumor sample, either archival (obtained within 6 months to joining study) or fresh biopsy.
- •For certain arms for Part 1, FGFR2b overexpression positive defined as any FGFR2b 2+/3+ TC determined by centrally performed immunohistochemistry (IHC), based on tumor sample provided.
- •For Part 2, FGFR2b overexpression positive defined as FGFR2b ≥10% 2+/3+ TC determined by centrally performed IHC testing, based on tumor sample provided.
- •Easter Cooperative Oncology Group (ECOG) performance score less than or equal to
- •Measurable or non-measurable disease as long as evaluable by Response Evaluation Criteria Solid Tumors (RECIST) version 1.1
- •Participant has no contradictions to CAPOX/SOX plus or minus nivolumab.
- •Adequate organ function.
- •For Part 2, measurable disease according to RECIST v1.1.
排除标准
- •Prior treatment for metastatic or unresectable disease (Note: prior adjuvant or neo-adjuvant therapy for local disease is allowed if ended more than 6 months of 1st dose).
- •Prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast growth factor receptor (FGF-FGFR) pathway.
- •Known human epidermal growth factor receptor 2 (HER2) positive
- •Untreated or symptomatic central nervous system (CNS) disease or brain metastases.
- •Peripheral sensory neuropathy greater than or equal to Grade
- •Clinically significant cardiac disease.
- •Other malignancy within the last 2 years (exceptions for definitively treated disease).
- •Chronic or systemic ophthalmological disorders.
- •Major surgery or other investigational study within 28 days of first study treatment dose.
- •Palliative radiotherapy within 14 days of first study treatment dose.
- •Abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer.
- •History or evidence of systemic disease or ophthalmological disorders requiring chronic use of ophthalmic corticosteroids.
研究组 & 干预措施
Part 1 Cohort D: Bemarituzumab with SOX and Nivolumab
Experimental
干预措施: SOX (Drug)
Part 1 Cohort A: Bemarituzumab with CAPOX
Experimental
干预措施: CAPOX (Drug)
Part 1 Cohort C: Bemarituzumab with CAPOX and Nivolumab
Experimental
干预措施: CAPOX (Drug)
Part 2: Bemarituzumab with SOX and Nivolumab.
Experimental
干预措施: SOX (Drug)
Part 1 Cohort C: Bemarituzumab with CAPOX and Nivolumab
Experimental
干预措施: Nivolumab (Drug)
Part 1 Cohort A: Bemarituzumab with CAPOX
Experimental
干预措施: Bemarituzumab (Drug)
Part 1 Cohort C: Bemarituzumab with CAPOX and Nivolumab
Experimental
干预措施: Bemarituzumab (Drug)
Part 1 Cohort D: Bemarituzumab with SOX and Nivolumab
Experimental
干预措施: Bemarituzumab (Drug)
Part 1 Cohort D: Bemarituzumab with SOX and Nivolumab
Experimental
干预措施: Nivolumab (Drug)
Part 2: Bemarituzumab with SOX and Nivolumab.
Experimental
干预措施: Nivolumab (Drug)
Part 2: Bemarituzumab with SOX and Nivolumab.
Experimental
干预措施: Bemarituzumab (Drug)
结局指标
主要结局
Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
时间窗: Day 1 to end of treatment (up to approximately 1 year)
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
时间窗: Day 1 up to Day 21
Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
时间窗: Up to 30 Months
次要结局
- Part 1: Area Under the Concentration-time Curve (AUC) of Bemarituzumab(Day 1 to end of treatment (up to approximately 1 year))
- Part 1: Duration of Response (DoR) per RECIST v1.1(Up to 2 years)
- Part 2: PFS per RECIST v1.1(Up to 30 months)
- Part 1: Maximum Observed Concentration (Cmax) of Bemarituzumab(Day 1 to end of treatment (up to approximately 1 year)))
- Part 1: Observed Concentration at the end of a Dose Interval (Ctrough) of Bemarituzumab(Day 1 to end of treatment (up to approximately 1 year))
- Part 2: Number of Participants Who Experience TEAEs(Up to 30 months)
- Part 2: DoR per RECIST v1.1(Up to 30 months)
- Part 2: Time to Response (TTR) per RECIST v1.1(Up to 30 months)
- Part 1: OR per RECIST v1.1(Up to 2 years)
- Part 1: Progression-free Survival (PFS) per RECIST v1.1(Up to 2 years)
- Part 1: Overall Survival (OS)(Up to 2 years)
- Part 2: Disease Control (DC) per RECIST v1.1(Up to 30 months)
- Part 1: Disease Control Rate (DCR)(Up to 2 years)
- Part 2: OS(Up to 30 months)
研究者
研究点 (42)
Loading locations...
相似试验
终止
1 期
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)Squamous-Cell Non-Small-Cell Lung CancerNCT05267470Amgen74
终止
1 期
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionSolid TumorsNCT05325866Amgen260
终止
3 期
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.Gastric CancerGastroesophageal Junction AdenocarcinomaNCT05111626Amgen515
进行中（未招募）
1 期
Standard of Care Chemotherapy Plus Pembrolizumab for Breast CancerTriple Negative Breast CancerNCT02734290Providence Health & Services29
已完成
1 期
A Study of LY3532226 in Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT05407961Eli Lilly and Company90